Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of 2616.HK is 8.9 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell